DEA Denies Registration to Dispensary in a Dual-License State

The Drug Enforcement Administration has told a Minneapolis dispensary it cannot receive the federal registration the agency began handing out to medical cannabis businesses last week, because Minnesota issues a single license covering both medical and adult-use sales. The refusal, contained in an order to show cause signed by Cheri Oz, assistant administrator of DEA's Diversion Control Division, arrived days after the Justice Department announced registrations for more than 900 dispensaries in seven states whose programs are medical-only.

The order states that Minnesota's "dual-purpose marijuana license, permitting both medical and non-medical dispensing falls outside the recent promulgated definition of 'state medical license.'" The document was first reported by the Minnesota Star Tribune.

Three reasons, one definition

The agency's reasoning in the In-Dispensary matter rests on a chain of conclusions about what a federal registration would endorse. Granting one, the order says, "would be inconsistent with the [Controlled Substances Act] as well as United States' treaty obligations."

Its central claim is that a license authorizing adult-use sales alongside medical sales cannot provide what the agency calls robust protections against diversion. "By allowing the dispensing of marijuana for non-medical purposes concomitant with and under the same state license as dispensing for medical purposes, the State of Minnesota's regime not only lacks 'robust protections against diversion,' but also lacks the capacity to achieve the public interest objectives underlying the CSA's registration framework," the order reads. Registering such an applicant, DEA continued, would mean registering "the state authority to dispense a controlled substance for non-medical purposes — constituting per se diversion under the CSA."

Two narrower features of Minnesota law drew separate objections. The state lets military veterans obtain medical cannabis by submitting veteran identification and an attestation that they have been diagnosed with a qualifying condition, without a written certification from a practitioner. The order also says the state "permits dispensaries to dispense synthetic marijuana products," a reference to hemp-derived cannabinoids.

Why seven states cleared and Minnesota did not

Friday's registrations went to businesses in Alabama, Florida, Mississippi, South Dakota, Texas, Virginia and West Virginia — states that permit medical cannabis while prohibiting recreational sales. Virginia is a partial exception: it enacted adult-use sales legislation this year but has not begun licensing retailers.

The pattern is the point. Federal registration under the attorney general's April 23 order is not a judgment about cannabis policy in general; it is a finding that a state's medical program is separable from non-medical commerce and can be supervised as a schedule III activity. Where a state fuses the two into one license, the agency says it has nothing it can register without also registering conduct it considers diversion.

What the dispensary can still do

In-Dispensary has 30 days to request a hearing to dispute the decision, or it can submit a corrective action plan instead. The order does not disturb state law.

The Minnesota Office of Cannabis Management told the Star Tribune that the federal order "does not impact the state law that authorizes Minnesota's medical cannabis and adult-use cannabis programs," adding that "medical cannabis remains available to patients in the state." The office described Minnesota's regulatory program as one that prioritizes public health and safety and could serve as a model for other states.

That framing is accurate as far as it goes: patients in Minnesota can still obtain medical cannabis under state law. What they cannot do, for now, is buy it from a business holding federal registration — and those businesses lose the protections and tax posture that come with the rescheduling framework.

The bigger map the order draws

The decision puts operators in dual-license states in an awkward position that the Justice Department's announcement did not address. Businesses in those states may be lawful under state law, may serve patients with qualifying conditions, and still be ineligible for the federal credential their counterparts in medical-only states just received.

It also raises a question about what any broader rescheduling would deliver. A DEA hearing that recently concluded testimony is weighing rescheduling beyond the medical framework, but adult-use programs do not issue written practitioner certifications of the kind the agency faulted Minnesota for relaxing. On DEA's reasoning, that gap is not a technicality — it is the distinction between a medical program the agency can supervise and a commercial market it says it cannot.

For patients, the practical effect of the order is indirect. Registration changes the legal exposure of the business, not the state-law availability of the product; a dispensary that loses federal registration does not close. But a market in which a large share of dispensaries cannot obtain federal standing is a market where the benefits that come with rescheduling accrue unevenly, and where the businesses serving chronic pain patients in those states may be the last to see them.

For background on the registrations that did go through, see our report on the 900-plus dispensaries. Readers looking for treatment for opioid use disorder can find medication-assisted treatment programs and information on substance use disorder elsewhere on the site.